ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: While several BCR-ABL inhibitors (e.g., imatinib, dasatinib, bosutinib, nilotinib, asciminib) are highly effective in chronic myeloid leukemia (CML) (Wei et al., 2010; Keskin et al., 2016), many patients develop drug resistance due to mutations in the BCR-ABL gene (Hantschel et al., 2012).